Allergic & Inflammatory Diseases
Transforming the treatment landscape in type 2 inflammatory diseases and beyond
The immune system plays a critical role in human health. Issues can occur, however, when the system becomes dysregulated, either promoting an uncontrolled “over” response or, inversely, failing to respond and protect the body appropriately. Our research focuses on understanding the cellular and molecular mechanisms that drive the pathology of allergic and inflammatory diseases that arise due to a dysregulated immune system. Our innovation in this category has led us to an ever-deepening clinical portfolio exploring potential new options for the treatment of allergy, autoimmune diseases and even cancer immunology.
Our commitment to type 2 inflammation research
At Regeneron, we have a rich history at the forefront of type 2 inflammation research. Multiple Phase 3 trials confirmed that the interleukin-4 (IL-4) and IL-13 pathways are central drivers of type 2 inflammation. This type of inflammation plays a major role in multiple and often comorbid diseases including atopic dermatitis, asthma, chronic obstructive pulmonary disease (COPD), prurigo nodularis and chronic rhinosinusitis with nasal polyps.
We continue to study other type 2 inflammatory diseases such as chronic spontaneous urticaria, bullous pemphigoid and chronic pruritis of unknown origin, striving to transform the treatment landscape.
We also have conducted significant research on the role of interleukin-6 (IL-6) in the treatment of chronic inflammatory conditions such as rheumatoid arthritis and polymyalgia rheumatica. When levels of IL-6 are elevated, it can disrupt homeostasis in a wide variety of physiological processes and persistent elevation can contribute to articular and systemic effects of rheumatoid arthritis. We are also exploring the role of IL-33 to address COPD in former smokers, regardless of eosinophilic phenotype.
Changing the Paradigm in COPD: Rethinking the Science & Removing Barriers
Committed to a patient-centered and science-forward approach
Research in allergic diseases
Our pipeline includes investigational treatments for diseases with high unmet need, including severe pet and environmental allergies. We are exploring a potential treatment approach for severe food allergies using a novel combination of monoclonal and bispecific antibodies.